Atossa Genetics Inc. (ATOS) Social Stream

Atossa Genetics Inc. (ATOS): $0.75

0.01 (+1.61%)

POWR Rating

Component Grades








Add ATOS to Watchlist
Sign Up

Industry: Biotech




#288 of 359

in industry

ATOSSA THERAPEUTICS INC (ATOS) Price Targets From Analysts

The tables below show the price targets and recommendations analysts covering ATOS.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-06-25 1 $7 $7 $7 $0.771 807.91%
2022-04-08 1 $4 $4 $4 $0.771 418.81%
2023-09-08 1 $5 $5 $5 $0.771 548.51%
NA 1 $NA $NA $NA $0.771 NA%

Price Target Last Issued September 8, 2023

The Trend in the Analyst Price Target

ATOS's average price target has moved up $1 over the prior 41 months.

500 - Internal server error

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2023-09-08 1 5 5 5 0.834 499.52%

ATOS Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1 1 0 0 0 0 1

The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for ATOS as an investment opportunity.

  • To contextualize these metrics, consider that out of all US stocks, ATOSSA THERAPEUTICS INC's number of analysts covering the stock is greater than practically none of them.
  • ATOS has a lower variance in analysts' estimates than almost 100% of all US stocks.
  • ATOSSA THERAPEUTICS INC's average analyst price target is greater than 23.27% of Healthcare stocks.
  • In the context of stocks in the small market cap category, ATOSSA THERAPEUTICS INC's upside potential (average analyst target price relative to current price) is greater than 246.32% of them.

In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to ATOSSA THERAPEUTICS INC are NHWK, ACRX, and IBIO.

Is ATOS a Buy, Hold or Sell? See the POWR Ratings now!

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!